Metastasis Awakening: The challenges of targeting minimal residual cancer

2013 ◽  
Vol 19 (3) ◽  
pp. 274-275 ◽  
Author(s):  
Bernhard Polzer ◽  
Christoph A Klein
Keyword(s):  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Minimal Residual

scholarly journals Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer

2021 ◽  
Author(s):  
Dongbin Zhao ◽  
Pinli Yue ◽  
Tongbo Wang ◽  
Pei Wang ◽  
Qianqian Song ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Cancer Cells ◽  
Peritoneal Lavage ◽  
Peritoneal Dissemination ◽  
Lavage Fluid ◽  
Residual Cancer ◽  
Peritoneal Lavage Fluid ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Abstract Peritoneal dissemination (PD) is the major type of gastric cancer (GC) recurrence and leads to rapid death. Current approach cannot precisely determine which patients are at high risk of PD. In this study, we developed a technology to detect minimal residual cancer cells in peritoneal lavage fluid (PLF) samples by parallel profiling tumor-specific mutations. We applied the technology to a prospective cohort of 110 GC patients. The technology showed ultra-high sensitivity by successfully detecting all the 27 cases that developed PD. The minimal residual cancer cells in PLF was associated with an increased risk of PD (HR = 145.13; 95%CI = 20.20-18435.79; p < 0.001) and significantly shorter overall survival. In pathologically high-risk (T4) patients, the PLF mutation profiling model exhibited even greater specificity of 91% and positive predictive value of 88%, while retaining sensitivity of 100%. PLF cancer cell fraction remained the strongest independent predictor of PD and recurrence-free survival over pathologic diagnosis and cytological diagnosis in GC patients. This approach may help in the postsurgical management of GC patients by detecting PD far before the metastatic lesions grow to significant size detectable by conventional methods such as MRI and CT scanning.

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer

The Lancet ◽  
2002 ◽  
Vol 360 (9334) ◽  
pp. 683-689 ◽  
Author(s):  
Christoph A Klein ◽  
Thomas JF Blankenstein ◽  
Oleg Schmidt-Kittler ◽  
Marco Petronio ◽  
Bernhard Polzer ◽  
...  
Keyword(s):  
Genetic Heterogeneity ◽  
Tumour Cells ◽  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Disseminated Tumour Cells ◽  
Minimal Residual

scholarly journals Transcriptome and genome analysis of single disseminated tumor cells: approach to study minimal residual cancer

10.1038/87156 ◽  
2001 ◽  
Vol 27 (S4) ◽  
pp. 65-65
Author(s):  
Christoph Klein ◽  
Stefan Seidl ◽  
Karina Petat-Dutter ◽  
Oleg Schmidt-Kittler ◽  
Sonja Offner ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Genome Analysis ◽  
Disseminated Tumor Cells ◽  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Independent Prognostication and Therapy Monitoring of Breast Cancer Patients by Dna/Rna Typing of Minimal Residual Cancer Cells

2000 ◽  
Vol 15 (1) ◽  
pp. 94-99 ◽  
Author(s):  
M. Giesing ◽  
F. Austrup ◽  
B. BÖckmann ◽  
G. Driesel ◽  
C. Eder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Molecular Characterization ◽  
Therapy Monitoring ◽  
Breast Cancer Patients ◽  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Clinical relevance, purification techniques and molecular characterization of minimal residual cancer cells (MRCC) is a controversial topic in the literature. An analytical concept including a novel isolation procedure and a panel of tests for DNA and RNA typing of MRCCs is described and clinically evaluated in this paper. The purification procedure exploiting the physical characteristics of MRCCs shows superior performance leading to >50% pure and viable tumor cells. Proof of the presence and purity of MRCCs in an isolated sample is given by multiparametric DNA typing (amplifications, mutations, losses of heterozygosity). On the basis of the proven presence of MRCCs tumor-relevant mRNAs can be adequately analyzed by normalized quantitative real-time RT-PCR. The molecular characterization of MRCCs isolated from blood of breast cancer patients could have a strong clinical impact on prognostication, drug targeting and therapy monitoring.

Sign in / Sign up

Export Citation Format

Share Document